68Ga-FAPI PET/CT在骨髓纤维化疾病评估中的应用价值
一项前瞻性临床研究纳入22例骨髓纤维化患者行68Ga-FAPI PET/CT,测量骨髓与脾脏摄取并与实验室、细胞遗传学及组织病理学数据比较。骨髓68Ga-FAPI摄取与骨髓纤维化分级显著正相关(r>0.8,P<0.001),0-1级患者视觉阴性、2-3级视觉阳性但受累程度不一。68Ga-FAPI PET/CT有望用于无创可视化和量化骨髓纤维化,并提供合适的骨髓活检部位,但其预后评估价值尚需进一步确认。
要点
- 22例骨髓纤维化患者行68Ga-FAPI PET/CT,骨髓摄取与纤维化分级显著正相关(r>0.8,P<0.001)。
- 0-1级骨髓纤维化患者68Ga-FAPI PET/CT视觉阴性,2-3级视觉阳性但受累程度不一。
- 68Ga-FAPI PET/CT可无创显示全身骨髓受累范围、区分纤维化早期与晚期,并提供骨髓活检部位。
核心结论
- 68Ga-FAPI PET/CT有望成为可视化和量化骨髓纤维化的方法,并提供合适的骨髓活检部位。
- 骨髓68Ga-FAPI摄取随骨髓纤维化进展而增加,是一种可用于评估骨髓纤维化进展的简单无创测量方法。
- 尽管68Ga-FAPI PET/CT已显示出在预后评估中的潜在价值,但仍需进一步确认。
研究设计与样本
- 这是一项前瞻性临床研究,纳入22例骨髓纤维化患者,均行68Ga-FAPI PET/CT。
- 测量患者各自骨髓和脾脏的68Ga-FAPI摄取,并将所得影像学发现与实验室、细胞遗传学及组织病理学数据进行比较。
主要发现
- 骨髓68Ga-FAPI摄取与骨髓纤维化分级呈显著正相关(r>0.8,P<0.001)。
- 68Ga-FAPI PET/CT在0-1级骨髓纤维化患者中显示视觉阴性结果,在2-3级患者中显示阳性,但受累程度不一。
- 68Ga-FAPI PET/CT提供了无创可视化全身骨髓受累范围并区分纤维化早期与晚期的手段。
关键数值与推荐
- 骨髓68Ga-FAPI摄取与骨髓纤维化分级显著正相关(r>0.8,P<0.001)。
- 68Ga-FAPI PET/CT视觉结果:0-1级骨髓纤维化为阴性,2-3级为阳性但受累程度不一。
临床怎么用
- 原文结论指出68Ga-FAPI PET/CT有望用于可视化和量化骨髓纤维化,并提供合适的骨髓活检部位。
- 原文结论指出骨髓68Ga-FAPI摄取随骨髓纤维化进展而增加,可作为评估骨髓纤维化进展的简单无创测量方法。
- 原文结论指出68Ga-FAPI PET/CT在预后评估中已显示潜在价值,但仍需进一步确认。
局限性
- 原文结论指出尽管68Ga-FAPI PET/CT已显示在预后评估中的潜在价值,但仍需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein is highly expressed in neoplastic lesions and various fibrotic tissues, making it an attractive target for disease evaluation. 68 Ga-labeled fibroblast activation protein inhibitor (FAPI), a new tumor interstitial imaging agent, holds promise for evaluating myelofibrosis. Therefore, this study aimed to use 68 Ga-FAPI PET/CT for the noninvasive visualization and quantification of the extent of myelofibrosis. PATIENTS AND METHODS: This was a prospective clinical study involving 22 patients with myelofibrosis who underwent 68 Ga-FAPI PET/CT. The uptake of 68 Ga-FAPI was measured in their respective bone marrow and spleen, and the obtained imaging findings were compared with laboratory, cytogenetic, and histopathological data. RESULTS: 68 Ga-FAPI uptake in the bone marrow was significantly and positively correlated with the myelofibrosis grade ( r > 0.8, P < 0.001). 68 Ga-FAPI PET/CT showed visually negative results in patients with grades 0-1 myelofibrosis and positive in those with grades 2-3, but the level of involvement varied. 68 Ga-FAPI PET/CT provides a noninvasive means of visualizing the extent of systemic bone marrow involvement and differentiation between the early and advanced stages of fibrosis. CONCLUSIONS: 68 Ga-FAPI PET/CT shows promise as a method for visualizing and quantifying myelofibrosis, providing suitable sites for bone marrow biopsy. The extent of 68 Ga-FAPI uptake by bone marrow increases with the progression of myelofibrosis, thus it is a simple and noninvasive measurement that can be used to evaluate the progression of myelofibrosis. Nevertheless, although 68 Ga-FAPI PET/CT has demonstrated a potential value in prognostic assessment, further confirmation is needed.
引用
- Liu Y, Li X, Jing L, et al. Application Value of 68 Ga-FAPI PET/CT in the Evaluation of Myelofibrotic Diseases. Clin Nucl Med. 2024. PMID: 38465921. doi:10.1097/RLU.0000000000005120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。